Edition:
India

Biomerica Inc (BMRA.OQ)

BMRA.OQ on NASDAQ Stock Exchange Capital Market

4.05USD
19 Apr 2018
Change (% chg)

-- (--)
Prev Close
$4.05
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
14,943
52-wk High
$9.32
52-wk Low
$2.27

Chart for

About

Biomerica, Inc. is a biomedical company, which develops, manufactures and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The Company's medical diagnostic products are sold around the world in over two markets, including clinical laboratories and point of... (more)

Overall

Beta: -0.58
Market Cap(Mil.): $24.61
Shares Outstanding(Mil.): 8.52
Dividend: --
Yield (%): --

Financials

BRIEF-Biomerica Q3 Sales $1.376 Million Versus $1.5 Million

* Q3 SALES $1.376 MILLION VERSUS $1.5 MILLION Source text for Eikon: Further company coverage:

17 Apr 2018

BRIEF-Biomerica Says ‍Mexico's Cofepris' Approval Of EZ Detect Colorectal Screening Test​ - SEC Filing

* BIOMERICA SAYS ‍MEXICO'S COFEPRIS' APPROVAL OF EZ DETECT COLORECTAL SCREENING TEST​ - SEC FILING

08 Mar 2018

BRIEF-Biomerica Q2 Loss Per Share $0.03

* BIOMERICA ANNOUNCES SECOND QUARTER FINANCIAL RESULTS; SALES UP 12.7% FOR THE QUARTER

16 Jan 2018

BRIEF-China FDA Approves Biomerica Colorectal Screening Test To Help Identify The Early Warning Signs Of Colorectal Cancer

* CHINA FOOD AND DRUG ADMINISTRATION (CFDA) APPROVES BIOMERICA COLORECTAL SCREENING TEST TO HELP IDENTIFY THE EARLY WARNING SIGNS OF COLORECTAL CANCER Source text for Eikon: Further company coverage:

10 Jan 2018

BRIEF-Biomerica Enters Into At Market Issuance Sales Agreement With B. Riley FBR

* BIOMERICA INC - ‍ON DEC. 1, 2017, CO ENTERED INTO AN AT MARKET ISSUANCE SALES AGREEMENT WITH B. RILEY FBR, INC - SEC FILING​

04 Dec 2017

BRIEF-Biomerica extends license agreement with Celtis Pharm

* Biomerica extends exclusive license agreement with Celtis Pharm (Telcon Pharmaceuticals) to December 2019

07 Nov 2017

Earnings vs. Estimates